2024 Preview: Are We There Yet?
After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […]
In Case You Missed It: Three Things We Learned in Our CDMO Webinar
If you missed it, the recording is available here. If you’re short on time, here are three of the key points that I took away from the session. Our speakers included Amanda Micklus from the Norstella consulting team, and Vince Spurr, one of our CDMO experts. Perhaps more importantly, we were joined by Matt Hewitt […]
In Sickness and in Health: The CDMO/Pharma Relationship
There are two inflection points where a pharma or biotech company looks to a CDMO. In one instance, it’s a technology transfer to create regional or incremental capacity, helping reduce the risk of a single-source manufacturing process. While this isn’t risk-free, it’s relatively straightforward. In recent years, though, we’ve seen an increase in companies seeking […]
Themes from BIO Europe
There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]
Meet the Evaluate Team: Alex Bour
Alex Bour leads Evaluate’s Competitive Intelligence consulting practice, working closely with clients to help them to understand the nuances of their competitive environment and helping them to craft effective strategies. When you don’t find him knee-deep in Evaluate data, or pondering the latest in gene and cell therapy, you might discover him in the kitchen […]
Quick View: Biopharma Dealmaking in Q3
The first half of the year showed some promise. Did the third quarter continue the trend? Well… If you read our round up of the state of the biopharma market at the halfway point of the year, you may have come away with, if not a spring in your step, then a least a little […]
Meet the Evaluate Team: Jim Chuck
Over four years into his Evaluate career, we thought it was time to find out a little more about Jim Chuck, one of our sales leaders who helps ensure that our clients find value in our solutions. He’s been working with and leading commercial functions for over 20 years and as well as being extremely […]
CI Meets AI at Pharma CI
Last month saw many of the world’s leading pharma and biotech companies deploy their competitive intelligence (CI) specialists to Newark. Specifically, to the Pharma CI Conference and Exhibition that took place on 20th and 21st of September. I joined them, and it was one of the best iterations of the conference that I’ve been to […]
In Case You Missed It: Three Things We Learned In Our World Preview Webinar
You may have read the report, you may have pondered the infographic, but the best way to really get under the skin of the Evaluate World Preview report is to join the webinar. As well as sharing the highlights of the data from the report, the webinar gave our presenters a chance to really discuss […]
CDMO Focus: Three Areas to Drive Success
CDMOs (Contract Development and Manufacturing Organisations) are key players in the biopharma market, playing a vital role in translating science into medicines that change people’s lives. Almost all pharma and biotech companies rely on CDMO services to some extent, whether that’s for clinical trials or huge marketed drugs. However, CDMOs view the market through a […]
